Alison Fraser

Alison Fraser

Auto-generated profile, based on publicly available information

Alison Fraser

University of Utah Huntsman Cancer Institute, Salt Lake City, UT

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2022 in Historical Life Course Studies
Verified
Journal Article
Open access
PDF file
KSKen R Smith
Ken R Smith
AFAlison Fraser
Alison Fraser
DRDiana Lane Reed
Diana Lane Reed
JBJahn Barlow
Jahn Barlow
HHHeidi A. Hanson
Heidi A. Hanson
GMGeraldine P. Mineau
Geraldine P. Mineau
Improving our understanding of the socio-environmental and genetic bases of disease and health outcomes among individuals, families, and populations over time requires extensive longitudinal data on multiple attributes for entire communities, states or nations. This requirement can be difficult to achieve. In this paper we describe a successful example of a database that meets these needs. The Utah Population Database (UPDB) is a unique and powerful database rarely found in the world that has been addressing these data requirements for over 40 years. The UPDB at the University of Utah is one of the world’s richest sources of in-depth information that supports research on genetics, epidemiology, demography, history, and public health. Genetic researchers have used UPDB to identify and study individuals and families that have higher than normal incidence of diseases or other traits, to analyze patterns of genetic inheritance, and to identify specific genetic mutations. Demographers and other social scientists are increasingly using the UPDB to study issues such as trends in fertility transitions and shifts in mortality patterns for both infants and adults. A central component of the UPDB is an extensive set of Utah family histories, in which family members are linked to demographic and medical information. The UPDB includes medical information about cancer, causes of death, and medical details associated with births. It also includes diagnostic records from statewide insurance claims data and healthcare facilities (hospital discharge, ambulatory surgery, emergency department encounters). UPDB is also linked to Medicare claims data, a federal health insurance program generally for persons age 65 or older. The UPDB provides access to information on more than 11 million individuals and supports nearly 400 research projects. We describe in detail the data components of the UPDB, how it can be accessed, issues related to its development, record linkage, governance and privacy protections, as well as plans for future developments.

27 June 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
EYErin L. Young
Erin L. Young
BTBryony Thompson
Bryony Thompson
DNDeborah W. Neklason
Deborah W. Neklason
MFMatthew A. Firpo
Matthew A. Firpo
TWTheresa Werner
Theresa Werner
STSean V. Tavtigian
Sean V. Tavtigian
Genes associated with hereditary breast and ovarian cancer (HBOC) and colorectal cancer (CRC) predisposition have been shown to play a role in pancreatic cancer susceptibility. Growing evidence suggests that pancreatic cancer may be useful as a sentinel cancer to identify families that could benefit from HBOC or CRC surveillance, but to date pancreatic cancer is only considered an indication for genetic testing in the context of additional family history. Preliminary data generated at the Huntsman Cancer Hospital (HCH) included variants identified on a custom 34-gene panel or 59-gene panel including both known HBOC and CRC genes for respective sets of 66 and 147 pancreatic cancer cases, unselected for family history. Given the strength of preliminary data and corresponding literature, 61 sequential pancreatic cancer cases underwent a custom 14-gene clinical panel. Sequencing data from HCH pancreatic cancer cases, pancreatic cancer cases of the Cancer Genome Atlas (TCGA), and an unselected pancreatic cancer screen from the Mayo Clinic were combined in a meta-analysis to estimate the proportion of carriers with pathogenic and high probability of pathogenic variants of uncertain significance (HiP-VUS). Approximately 8.6% of unselected pancreatic cancer cases at the HCH carried a variant with potential HBOC or CRC screening recommendations. A meta-analysis of unselected pancreatic cancer cases revealed that approximately 11.5% carry a pathogenic variant or HiP-VUS. With the inclusion of both HBOC and CRC susceptibility genes in a panel test, unselected pancreatic cancer cases act as a useful sentinel cancer to identify asymptomatic at-risk relatives who could benefit from relevant HBOC and CRC surveillance measures.

30 June 2022 in Cancer Medicine
Verified
Journal Article
Open access
SHSiqi Hu
Siqi Hu
DBDavid Baraghoshi
David Baraghoshi
CCChun‐Pin Chang
Chun‐Pin Chang
KRKerry Rowe
Kerry Rowe
JSJohn Snyder
John Snyder
MHMia Hashibe
Mia Hashibe
Background: Ovarian cancer is the fifth most common female cancer in the United States. There have been very few studies investigating mental health diagnoses among ovarian cancer survivors with long‐term follow up. The aim of this study is to examine the incidence of mental illness among ovarian cancer survivors compared to a general population cohort. A secondary aim is to investigate risk factors for mental illnesses among ovarian cancer survivors.Patients and methods: Cohorts of 1689 ovarian cancer patients diagnosed between 1996 and 2012 and 7038 women without cancer matched by age and birth state from the general population were identified. Mental health diagnoses were identified from electronic medical records and statewide healthcare facilities data. Cox proportional hazard models were used to estimate hazard ratios (HRs).Results: Ovarian cancer survivors experienced increased risks of mental illnesses within the first 2 years after cancer diagnosis (HR = 3.55, 95% CI = 3.04–4.14). The risks of depression among ovarian cancer survivors were nearly 3‐fold within the first 2 years of cancer diagnosis (HR = 2.59, 95% CI = 1.94–3.47), and 1.69‐fold at 2–5 years after cancer diagnosis (HR = 1.69, 95% CI = 1.18–2.42). Ovarian cancer survivors experienced an 80% increased risk of death with a mental illness diagnosis (HR = 1.80, 95% CI = 1.48–2.18) and a 94% increased risk of death with a depression diagnosis (HR = 1.94, 95% CI = 1.56–2.40).Conclusions: Higher risks of mental illnesses were observed among ovarian cancer survivors throughout the follow‐up periods of 0–2 years and 2–5 years after cancer diagnosis. Multidisciplinary care is needed to monitor and treat mental illnesses among ovarian cancer survivors.

18 September 2019 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
SGSamantha Greenberg
Samantha Greenberg
SBSaundra S. Buys
Saundra S. Buys
SESandra L. Edwards
Sandra L. Edwards
WEWhitney Espinel
Whitney Espinel
AFAlison Fraser
Alison Fraser
CSCarol Sweeney
Carol Sweeney
Background: Personal cancer diagnosis and family cancer history factor into which individuals should undergo genetic testing for hereditary breast and ovarian cancer (HBOC) syndrome. Family history is often determined in the research setting through kindreds with disease clusters, or clinically from self‐report. The population prevalence of individuals with diagnostic characteristics and/or family cancer history meeting criteria for HBOC testing is unknown.Methods: Utilizing Surveillance, Epidemiology, and End Results (SEER) cancer registry data and a research resource linking registry records to genealogies, the Utah Population Database, the population‐based prevalence of diagnostic and family history characteristics meeting National Comprehensive Cancer Network (NCCN) criteria for HBOC testing was objectively assessed.Results: Among Utah residents with an incident breast cancer diagnosis 2010‐2015 and evaluable for family history, 21.6% met criteria for testing based on diagnostic characteristics, but the proportion increased to 62.9% when family history was evaluated. The proportion of cases meeting testing criteria at diagnosis was 94% for ovarian cancer, 23% for prostate cancer, and 51.1% for pancreatic cancer. Among an unaffected Utah population of approximately 1.7 million evaluable for family history, 197,601 or 11.6% met testing criteria based on family history.Conclusions: This study quantifies the population‐based prevalence of HBOC criteria using objectively determined genealogy and cancer incidence data. Sporadic breast cancer likely represents a portion of the high prevalence of family cancer history seen in this study. These results underline the importance of establishing presence of a deleterious mutation in an affected family member, per NCCN guidelines, before testing unaffected relatives.

27 March 2019 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
MHMakenzie L Hawkins
Makenzie L Hawkins
BBBrenna E Blackburn
Brenna E Blackburn
KRKerry Rowe
Kerry Rowe
JSJohn Snyder
John Snyder
VDVikrant G Deshmukh
Vikrant G Deshmukh
MHMia Hashibe
Mia Hashibe
Background: There are an estimated 1.4 million colorectal cancer (CRC) survivors in the United States. Research on endocrine and metabolic diseases over the long term in CRC survivors is limited. Obesity is a risk factor for CRC; thus it is of interest to investigate diseases that may share this risk factor, such as diabetes, for long-term health outcomes among CRC survivors. Methods: A total of 7114 CRC patients were identified from the Utah Population Database and matched to a general population cohort of 25 979 individuals on birth year, sex, and birth state. Disease diagnoses (assessed over three time periods of 1–5 years, 5–10 years, and >10 years) were identified using electronic medical records and statewide ambulatory and inpatient discharge data. Cox proportional hazard models were used to estimate the risk of endocrine and metabolic disease. Results: Across all three time periods, risks for endocrine and metabolic diseases were statistically significantly greater for CRC survivors compared with the general population cohort. At 1–5 years postdiagnosis, CRC survivors’ risk for diabetes mellitus with complications was statistically significantly elevated (hazard ratio [HR] = 1.36, 99% confidence interval [CI] = 1.09 to 1.70). CRC survivors also experienced a 40% increased risk of obesity at 1–5 years postcancer diagnosis (HR= 1.40, 99% CI= 1.66 to 2.18) and a 50% increased risk at 5–10 years postdiagnosis (HR = 1.50, 99% CI= 1.16 to 1.95). Conclusions: Endocrine and metabolic diseases were statistically significantly higher in CRC survivors throughout the follow-up periods of 1–5 years, 5–10 years, and more than 10 years postdiagnosis. As the number of CRC survivors increases, understanding the long-term trajectory is critical for improved survivorship care.

1 April 2023 in Radiology
Verified
Journal Article
Closed access
YAYoshimi Anzai
Yoshimi Anzai
CCChun-Pin Chang
Chun-Pin Chang
KRKerry Rowe
Kerry Rowe
JSJohn Snyder
John Snyder
VDVikrant Deshmukh
Vikrant Deshmukh
MHMia Hashibe
Mia Hashibe
An analysis of Utah Cancer Registry and population data demonstrated that surveillance imaging with PET/CT and CT and/or MRI was associated with lower mortality of patients with head and neck cance... Background To the knowledge of the authors, no strong evidence supports surveillance imaging in patients with head and neck cancer (HNC). Purpose To investigate the association between surveillance...